Prasanna Sooriakumaran

Prasanna Sooriakumaran
About Prasanna Sooriakumaran
  • As life expectancy rises, greater numbers of older men with skeletal metastases from prostate cancer suffer higher treatment burdens. The current standard-of-care, androgen deprivation therapy (ADT), causes morbidity and might pose significant damage to bone and mental health. Better definition of burden-of-treatment from ADT will enable appropriate multi-disciplinary management and directly improve quality of care.
  • Dr. Prasanna Sooriakumaran is exploring an approach to the management of advanced, metastatic prostate cancer without compromising quality-of-life.
  • Dr. Sooriakumaran will launch a three-year observational study of 200 men with mCRPC to assess a model considering severity of bone lesions, age, anxiety and depression symptoms, co-morbidities, and treatment choices. Testing this model may lead to a predictive tool to guide clinicians in selecting personalized treatment.

What this means for patients: A model predicting quality-of-life for men with advanced metastatic prostate cancer will enable doctors to prescribe treatments on a personalized basis.

Award

2015 Howard Shore–PCF Young Investigator

Prasanna Sooriakumaran, MBBS, PhD

University of Oxford

Mentor

Freddie C. Hamdy, MD

Proposal Title

Improving Quality of Care for Men with Skeletal Metastases from Prostate Cancer: Defining the Burden-of-Treatment and its Management, and Developing Models to Predict Quality-of-Life

Features(1)